Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

(2012) Oran Erster et al.   JOURNAL OF CONTROLLED RELEASE

Marketed therapeutic antibodies compendium

(2012) Janice M. Reichert   mAbs

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

(2012) Andrea Cavazzoni et al.   Molecular Cancer

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imaging a functional tumorigenic biomarker in the transformed epithelium

(2012) A. M. LeBeau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

(2011) Y. Y. Janjigian et al.   CLINICAL CANCER RESEARCH

State of the Art in Tumor Antigen and Biomarker Discovery

(2011) Klervi Even-Desrumeaux et al.   Cancers

The safety and side effects of monoclonal antibodies

(2010) Trevor T. Hansel et al.   NATURE REVIEWS DRUG DISCOVERY

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities

(2009) Helmout Modjtahedi et al.   ANTI-CANCER DRUGS

The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

(2009) Salvatore Ulisse et al.   CURRENT CANCER DRUG TARGETS

Antibody-Drug Conjugate Targets

(2009) B. Teicher   CURRENT CANCER DRUG TARGETS

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma

(2008) Herbert Riechelmann et al.   ORAL ONCOLOGY